Delpeuch Amina, Leveque Dominique, Gourieux Benedicte, Herbrecht Raoul
Pharmacy Department, Strasbourg University Hospital, Strasbourg, France
Pharmacy Department, Strasbourg University Hospital, Strasbourg, France.
Anticancer Res. 2015 Jan;35(1):457-60.
BACKGROUND/AIM: Clinical pharmacists are contributing to safe medication use by providing comprehensive management to patients and medical staff. However, little is known regarding their impact in oncology. The aim of this study was to document and evaluate the role of clinical pharmacy services in a hematology/oncology department.
A prospective, descriptive, observational study was carried out from May 2012 to May 2013. Medication reviews concerning hospitalized adult cancer patients were performed twice a week. Medication problems, pharmaceutical interventions and acceptance rate by the oncologists were recorded by a clinical pharmacist.
A total of 4,393 prescriptions (including chemotherapy and support) of 489 adult cancer patients (mean age=63 years) were analyzed. The pharmacist identified 552 drug-related problems (12.6% of the prescriptions) primarily related to anti-infective agents (59.5%). Medication problems included inappropriate medications (20.6%), untreated indications (14.8%), inappropriate administrations (14.1%), underdosing (11.7%), drug-drug interactions (14.3%), lack of monitoring (9.6%), overdosing (8.9%), administration omissions (3.5%) and side-effects (2.5%). Interventions (n=552) led to treatment discontinuation (26.2%), drug dosing adjustments (21.5%), drug additions (16.9%), alternate routes of administration (11.7%), replacement of a drug by another one (10.7%), therapeutic drug monitoring (10.3%) and optimizing administration (2.6%). Most (96%) of the interventions were accepted and implemented by the medical staff.
The integration of clinical pharmacy services resulted in drug-specific interventions in 12.6 % of the prescriptions of hospitalized adult patients with cancer. Medication problems mostly concerned anti-infective agents. The intervention acceptance rate by oncologists was high. The outcome of care in the hematology/oncology inpatient setting remains to be measured.
背景/目的:临床药师通过为患者和医务人员提供全面管理,对安全用药发挥着作用。然而,关于他们在肿瘤学方面的影响却知之甚少。本研究的目的是记录和评估临床药学服务在血液学/肿瘤学部门中的作用。
于2012年5月至2013年5月开展了一项前瞻性、描述性观察研究。每周对住院成年癌症患者进行两次用药审查。临床药师记录用药问题、药学干预措施以及肿瘤学家的接受率。
共分析了489例成年癌症患者(平均年龄 = 63岁)的4393张处方(包括化疗和支持用药)。药师识别出552个与药物相关的问题(占处方的12.6%),主要与抗感染药物有关(59.5%)。用药问题包括用药不当(20.6%)、适应证未治疗(14.8%)、给药不当(14.1%)、剂量不足(11.7%)、药物相互作用(14.3%)、缺乏监测(9.6%)、剂量过量(8.9%)、给药遗漏(3.5%)和副作用(2.5%)。干预措施(n = 552)导致治疗中断(26.2%)、药物剂量调整(21.5%)、添加药物(16.9%)、改变给药途径(11.7%)、一种药物替换为另一种药物(10.7%)、治疗药物监测(10.3%)以及优化给药(2.6%)。大多数(96%)干预措施被医务人员接受并实施。
临床药学服务的整合在12.6%的住院成年癌症患者处方中产生了针对特定药物的干预措施。用药问题主要涉及抗感染药物。肿瘤学家对干预措施的接受率较高。血液学/肿瘤学住院患者的护理结果仍有待衡量。